The invention provides multispecific antigen-binding molecules having a specificity for a complex of matrix metallopeptidase 1 (MMP1) and the human leukocyte antigen A2 (HLA-A2), and a further specificity for engaging an immune effector cell, such as a T-cell via CD3 receptor or a NK-cell via CD16A receptor. The invention further includes such multispecific antigen binding molecules for use in immunotherapy, in particular for the treatment of a MMP1+ cancer.